BAYRY
JNJ
Courtroom 1, Bayer 0
Johnson & Johnson just dodged a fast-moving attempt by Bayer to yank its prostate cancer drug ads off the air. A U.S. judge in Manhattan rejected Bayer’s request for an injunction, which means J&J can keep touting Erleada while the bigger false-advertising fight plays out.
Why this matters
Bayer argued that J&J’s campaign overstated Erleada’s benefits and would unfairly damage Nubeqa, Bayer’s competing drug. But the judge said Bayer didn’t show it was likely to win on the merits, and that J&J’s communications matched the conclusions of its study closely enough.
The investor angle
This isn’t a blockbuster revenue event by itself, but it does matter because drug marketing can move minds, prescriptions, and eventually sales. If J&J keeps its messaging intact, Erleada keeps its shot at winning more share in a very lucrative market — and Bayer doesn’t get the immediate relief it wanted.
Big picture
The case is a reminder that in pharma, the battle isn’t just in the lab. It’s also in the courtroom, where a single judge can decide whether a commercial keeps running or gets yanked like a bad streaming show.